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Abstract 
The liver flukes Fasciola hepatica and F. gigantica infect livestock worldwide and 
threaten food security with climate change and problematic control measures 
spreading disease.  Fascioliasis is also a food borne disease with up to 17 million 
humans infected.  In the absence of vaccines, treatment depends on 
Triclabendazole (TCBZ) and over-use has led to widespread resistance, 
compromising future TCBZ control.  Reductionist biology from many laboratories has 
predicted new therapeutic targets. To this end, the fatty acid binding protein (FABP) 
superfamily have proposed multi-functional roles, including functions intersecting 
vaccine and drug therapy, such as immune modulation and anthelmintic 
sequestration.  Research is hindered by a lack of understanding of the full FABP 
superfamily complement.  Although discovery studies predicted FABPs as promising 
vaccine candidates, it is unclear if uncharacterised FABPs are more relevant for 
vaccine formulations.  We have coupled genome, transcriptome and EST data 
mining with proteomics and phylogenetics, to reveal a liver fluke FABP superfamily 
of 7 clades: previously identified clades I-III and newly identified clades IV-VII.  All 
new clade FABPs were analysed using bioinformatics and cloned from both liver 
flukes.  The extended FABP dataset will provide new study tools to research the role 
of FABPs in parasite biology and as therapy targets. 
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Introduction 
The trematode liver flukes, Fasciola hepatica and F. gigantica, are the 
causative agents of fasciolosis, a foodborne zoonotic disease affecting grazing 
animals and humans worldwide.  Liver fluke causes economic losses of over US$ 3 
billion worldwide per annum to livestock via mortality, reduction in host fecundity, 
susceptibility to other infections, decrease in meat, milk and wool production and 
condemnation of livers (1).  Liver fluke disease of livestock is increasing worldwide 
(2), with a number of potential contributing factors:  climate change (warmer winters 
and wetter summers supporting larger intermediate mud snail host populations); 
fragmented disease management (only treating sheep not cattle and limiting 
veterinary interaction); encouragement of wet-lands; livestock movement; and/or 
failure/resistance of chemical control treatments in the absence of commercial 
vaccines (3, 4). Fasciolosis is also a re-emerging human disease with estimates of 
between 2.4-17 million people infected worldwide (5-7).  Furthermore, worldwide 
livestock movement is providing new opportunities for the introduction of pathogenic 
isolates (4).   
Control of liver fluke is currently via anthelmintics.  The benzimidazole (BZM)-
derivative, triclabendazole (TCBZ), is the drug most extensively used against 
Fasciola. Unlike other fasciolicides, TCBZ shows activity against both juvenile flukes, 
which are responsible for the damage to the liver of acute fasciolosis, and the mature 
flukes which cause the debilitation of chronic fasciolosis (8). However, TCBZ 
resistant liver fluke are increasing throughout Europe and Australia, compromising 
control efforts (9-12).  Following end of patent protection, generic forms of TCBZ will 
likely lead to wider application, potential misuse and exacerbation of the spread of 
resistance.  
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The mode of action of TCBZ at the molecular level has yet to be resolved. 
Laboratories report a variety of biological effects of TCBZ on liver fluke (for reviews 
see 9, 13).  As well as increased efflux (14), enhanced biotransformation and 
metabolism of TCBZ has also been hypothesised to play a major role in 
detoxification and resistance.  Anthelmintic resistance can arise from efficient 
detoxification via Phase II and Phase III conjugation, sequestration and efflux 
mechanisms.  To this end, a type I FABP, Fh15 protein with sequestration potential 
is significantly upregulated on TCBZ exposure in resistant adult liver fluke (15) and a 
FABP from Schistosoma japonicum has been reported to play a role in Praziquantel 
drug binding (16).  Moreover, increased expression of FABP mRNA occurs in drug 
resistant strains of Anopheles gambiae during permethrin insecticide exposure (17). 
Thus, increased expression of FABP maybe a generic invertebrate response to drug 
challenge and a potential resistance marker.  
The soluble super family of fatty acid binding proteins (FABPs) are small (14–
15 kDa) proteins that bind or sequestrate hydrophobic ligands such as anthelmintics 
(16). The precise function of each FABP type remains imperfectly understood, since 
sub-specialization of functions is suggested.  At least nine distinct types of 
cytoplasmic FABPs have been identified in mammals, each showing a characteristic 
pattern of tissue distribution (18).  FABPs isolated from the same tissue of different 
vertebrate species show sequence identities of 70 % and higher, whereas FABPs 
isolated from different tissues of a single species have sequence similarity as low as 
20 %.  However, their tertiary structure is remarkably conserved, consisting of ten 
anti-parallel β-strands comprising a β-barrel (containing conserved amino acid 
residues that are involved in ligand binding) and a helix-turn-helix cap (16).  
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Importantly for vaccine candidature and drug sequestration, FABP is also an 
abundant component of the soluble tegumental proteome of adult liver fluke (19, 20).  
Vaccination against liver fluke remains at the research stage (21, 22).  Previous 
studies have placed cytosolic FABPs amongst the major potential vaccine 
candidates (23). Vaccine trials suggest that both native and recombinant F. hepatica 
FABPs induce significant levels of protection in different animal models against 
infection with F. hepatica and cross-protection against S. mansoni and S. bovis with 
anti-fluke, anti-fecundity and anti-pathology effects (23).  
The recent discovery of FABPs in the cargo of exosome-like vesicles released 
from adult F. hepatica (24), suggests new roles for parasite FABPs within host cells.  
In support of this hypothesis in vitro assays demonstrate FABP I (Fh12) alters 
behaviour of monocyte derived macrophages, with increased arginase 
expression/activity and an increase in chitinase-3-like protein (25).  FABP I also 
down regulated nitric oxide production and the expression of nitric oxide synthase in 
interacting cells exhibiting a potent anti-inflammatory effect in inducing the 
production of alternatively activated macrophages (25).  Furthermore, FABP I has 
been shown to suppress inflammatory cytokines in a model of septic shock 
potentially delivering its effect via binding to CD14 co-receptors (26). 
Despite growing evidence supporting the importance of FABPs for the establishment 
of liver fluke in the vertebrate host, our knowledge of the superfamily complement is 
fragmented even with many reductionist studies.  We report the mining of the 
genome, transcriptomic and EST datasets, supplemented with proteomics and 
phylogenetics, to systematically reveal the complexity and novelty within the liver 
fluke FABP superfamily.  Furthermore, we have identified which of these FABPs are 
recognised by the immune system for further vaccine discovery.  
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Experimental Procedures 
Fluke collection and cultures 
Adult F. hepatica were recovered from naturally infected ovine livers immediately 
post-slaughter from a local abattoir in Mid-Wales, UK. Fluke were washed several 
times in PBS at 37 °C to remove host material by regurgitation of gut contents as 
previously described (27).  Adult flukes were transported to the laboratory and 
maintained in Fasciola saline (FS; Dulbecco’s Modified Eagle’s Medium (DMEM) 
[w/o NaHPO3 and PO4] plus 2.2 mM Ca [C2H3O2], 2.7 mM MgSO4, 61.1 mM glucose, 
1 µM serotonin, 5 µgml-1 gentamycin, 15 mM N-2-Hydroxyethylpiperazine-N’-2-
ethanesulfonic acid (HEPES), pH 7.4) at 37 °C for 2 hrs. Metacercariae were 
purchased from Ridgeway Research and excysted following the physiological 
method outlined by Dixon (28, 29) and described previously (30). 
Cytosol preparations and 2DE 
F. hepatica  extracts were obtained by homogenisation of frozen fluke at 4°C in lysis 
buffer containing 20 mM Potassium phosphate, pH 7.4, 0.1% (v/v) Triton-X100 and 
protease inhibitors (Roche, Complete-Mini, EDTA-free).  After homogenisation, 
samples were centrifuged at 100,000 × g for 1 h at 4°C and the supernatant was 
termed the cytosolic fraction.  Cytosolic protein extracts were precipitated with an 
equal volume of ice-cold 20% TCA in acetone (w/v) and washed twice in ice-cold 
acetone before solubilisation into isoelectric focusing buffer (IEF buffer) consisting of 
8 M urea, 2% w/v CHAPS, 33 mM DTT and 0.5% carrier ampholytes v/v (Biolyte 3-
10, Bio-Rad) as described previously (31).  For preliminary 2DE, a total of 100 µg 
was passively in-gel rehydrated for 16 h and isoelectrically focused on 7 cm linear 
pH 3-10 IPG strips (BioRad) for 10,000 Vh.  For analytical 2DE a total of 500 µg of 
each replicate sample was passively in-gel rehydrated for 16 h and isoelectrically 
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focused on 17 cm pH 4.7-5.9 or 7-10 IPG strips (BioRad) to 60000 Vh.  All IEF was 
conducted on a Protean® IEF Cell (Bio-Rad).   
After focusing, strips were equilibrated for 15 min in reducing equilibration buffer 
(30% v/v glycerol, 6 M urea, 1% DTT) followed by 15 min in alkylating equilibration 
buffer (30% v/v glycerol, 6 M urea, 4% iodoacetamide).  IPG strips were run upon 
SDS-PAGE (14 % acrylamide) using the Protean® II xi 2D Cell (BioRad) for 17 cm or 
PROTEAN® Mini (Bio-Rad, UK) for 7 cm 2DE. Gels were Coomassie blue stained 
(Phastgel Blue R, Amersham Biosciences) and scanned on a GS-800 calibrated 
densitometer (BioRad). 
Gel image quantitative differences between protein spots were analysed via 
Progenesis PG220 software, version 2006 (Nonlinear Dynamics).  Spots were 
manually detected on gels with normalisation performed using total spot volume 
multiplied by 100.  Quantitative analysis was based on average gels created from 
four biological replicates.   
Protein identification 
Protein spots were manually excised and tryptically digested and prepared for mass 
spectrometry as previously described (32, 33).  Tandem mass spectrometry 
(MS/MS) was performed according to the method of Moxon et al. (34) followed by 
data processing for database searching. Samples prepared for liquid 
chromatography–tandem mass spectrometry (LC–MS/MS) were analysed using 
electrospray ionisation as previously reported (34). Peptide mixtures from trypsin 
digested gel spots were separated using a LCPackings Ultimate nano-HPLC 
System. Sample injection was via an LC Packings Famos auto-sampler and the 
loading sol-vent was 0.1% formic acid. The pre-column used was a LCPackings C18 
PepMap 100, 5 mm, 100 A and the nano HPLC column was a LC Packings PepMap 
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C18, 3 mm, 100 A. The solvent system was: solvent A (2% ACN with 0.1% formic 
acid), and solvent B (80% ACN with 0.1% formic acid). The LC flow rate was 0.2 
µL/min with a gradient employed using 5% sol-vent A to 100% solvent B in 1 h. The 
HPLC eluent was sprayed into the nano-ES source of a Waters Q-TOFµMS via a 
New Objective Pico-Tip emitter. The MS was operated in positive ion mode and 
multiply charged ions were detected using a data-directed MS/MS experiment. 
Collision induced dissociation (CID) MS/MS mass spectra were recorded over the 
mass range m/z 80–1400 Da with scan time 1 s. MassLynx v 3.5 (Waters, UK) 
ProteinLynx suite of tools was used to process raw fragmentation spectra. Each 
spectrum was combined and smoothed twice using the Savitzky–Golay method at ±3 
channels with background noise subtracted at polynomial order 15 and 10% below 
curve. Monoisotopic peaks were centred at 80% centroid setting. Sequest 
compatible (.dta) file peak mass lists for each spectrum were exported, and spectra 
common to each 2DE spot were merged into a single MASCOT generic format 
(.mgf) file using the on-line Peak List Conversion Utility available at 
www.proteomecommons.org. Merged files were submitted to a MASCOT MS/MS 
ions search within a locally installed Mascot server (www.matrixscience.com) to 
search an ‘in-house’ database constructed from 6260 (858 763 residues) F. hepatica 
EST sequences downloaded and translated from the Sanger Institute 
(ftp://ftp.sanger.ac.uk/pub/ pathogens/fasciola/hepatica/ESTs/). Search parameters 
were as described in Morphew et al. (33). 
Western blotting 
For Western blotting samples were prepared and separated according to the 
method described above. Proteins were transferred to HybondTM-C Extra 
nitrocellulose membrane (GE Healthcare) using a Trans-blot Cell (Bio-Rad) at 20 V 
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overnight. Transfer was carried out in 192 mM glycine (Sigma), 25 mM Tris base and 
20 % (v/v) methanol according to the method of Towbin et al. (35). The membrane 
was stained for 1 min 10 with 0.1 % (w/v) amido black 10B (Naphthol Blue Rack, 
Sigma) in 10 % (v/v) acetic acid and 25 % (v/v) isopropanol and destained in 10 % 
(v/v) acetic acid and 25 % (v/v) isopropanol to evaluate transfer efficiency. 
NC membranes were blocked in TTBS (0.1 M Tris base, pH = 7.5, 0.9 % (w/v) 
NaCl, 1 % (v/v) TweenR 20 (Acros)) containing 5 % (w/v) skimmed milk powder for a 
minimum of 4 h. Membranes were then washed in TTBS for 10 min before being 
incubated for 1 h with the primary antibody diluted at 1:5,000 in TTBS containing 1 % 
(w/v) skimmed milk powder. In all Western blots pooled, bovine, whole sera from 
Fasciola hepatica-challenged and naive cattle were used as described previously 
(36). 
Membranes were washed three times for 5 min in TBS (0.1 M Tris base, pH = 
7.5, 0.9 % (w/v) NaCl, 1 % (v/v)) to remove residual primary antibody and incubated 
for 1 h with anti-bovine IgG (whole molecule) conjugated to alkaline phosphatase 
(AKP, Sigma) diluted at 1:30,000 or anti-bovine IgM (whole molecule) conjugated to 
AKP (Novus Biologicals) diluted at 1:1,000 both in TTBS containing 1 % (w/v) 
skimmed milk powder. The membranes were again washed three times for 5 min in 
TBS. Visualisation of the resulting immuno-complexes was achieved by developing 
the membranes in 5-bromo-4-chloro-3-indolyl phosphate (BCIP; Sigma) and nitro 
blue tetrazolium (NBT; BDH, VWR Life Sciences) according to the manufacturer's 
instruction.  
Bioinformatics -Transcripts and Phylogenetics 
All sequence alignments were carried out using ClustalW multiple alignment 
(37) via BioEdit Version 7.0.9.0 (6/27/07) (38). Previously published FABP 
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sequences from both Fasciola species were retrieved from the Genbank database 
(http://www.ncbi.nlm.nih.gov/) and aligned with ESTs and transcripts from available 
sources (39)(ftp://ftp.sanger.ac.uk/pub/project/pathogens/Fasciola/hepatica/ESTs/; 
EBI-ENA archive ERP000012: An initial characterization of the F. hepatica 
transcriptome using 454-FLX sequencing). Transcripts and ESTs that matched at 
least one of the already known FABPs in a BLAST analysis were included in 
alignments. From the alignment a phylogenetic tree was constructed in MEGA v 4.0 
using a neighbor-joining method, 1000-replicate, bootstrapped tree. The amino acid 
data were corrected for a gamma distribution (level set at 1.0) and with a Poisson 
correction. 
Bioinformatics - Analysis of novel FABPs  
Secondary structure analysis of novel FABP isoforms was conducted using 
PSIPRED available at http://bioinf.cs.ucl.ac.uk/psipred/. Motif analysis was 
conducted using InterPro (40) and phosphorylation predictions using NetPhos 2.0 
(41). Sequences from F. hepatica and F. gigantica encoding novel FABP isoforms 
were also subjected to epitope predictions using a Kolaskar and Tongaonkar 
Antigenicity prediction method (42), available at http://tools.immuneepitope.org/tools/ 
bcell/iedb_input, and signal peptide analysis using the Signal P 4.1 server and a cut-
off point of 0.45 (43).  Intron-exon structures of novel F. hepatica FABP isoforms was 
also determined using Artemis (44) on sequences identified in the F. hepatica 
genome (45). 
Cloning 
Novel FABP isoforms from F. hepatica and F. gigantica were cloned using primers 
designed on F. hepatica and F. gigantica transcripts (FABP IV: forward primer 5′ 
ATG GAA GCA TTC GTC GGA 3′ and reverse primer 5′ TCA AAT TTT CTG GAA 
Page 10 of 47
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TTT GAA G 3′. FABP V: forward primer 5′ CGG GTC TCT GCC CTG TAT ATT 3′ 
and reverse primer 5′ TGT GAC GGG ATA AAC CCA AT 3′. FABP VI: forward 
primer 5′ TCG CCA TAT TGG TAC ATT 3′ and reverse primer 5′ CAT TTA ATG 
GGC GCC GCT 3′. FABP VII: forward primer 5′ TCA ACC ATG TCA AAG CTT AT 3′ 
and reverse primer 5′ GAC AAG CGG GTA CAT TCA TG 3′ or 5′ GAC AAG CTT 
GTA CAT TCA TG 3′). Fasciola FABP sequences were amplified using PCR. Both F. 
hepatica and F. gigantica sequences were then cloned into the pGEM-T easy vector 
(Promega) according to manufacturer’s instructions, screened and sequenced in-
house.  
Recombinant protein production and purification 
FABP IV and V from both fasciolids were amplified from plasmids containing 
inserts with the addition of Nde-I and Not-I restriction enzyme sites for directional 
cloning into the pET28a (Novagen) expression vector.  Recombinant FABP protein 
was expressed via the Escherichia coli BL21(DE3) and pET28a expression vector 
system (Novagen) and purified using nickel-affinity via a C-terminal polyhistadine tag 
as previously described (31).  Purity was assessed by electrospray ionisation (ESI) 
mass spectrometry and sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE).  
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Results  
Characterisation of FABP from F. hepatica ontogeny 
In order to effectively resolve the known FABP isoforms present in F. 
hepatica, both adult and newly excysted juveniles (NEJ) were subjected to 
preliminary 2D SDS-PAGE analysis using broad range IPG strips to localise FABP 
representatives.  Based upon previous 2D SDS-PAGE investigations into the FABP 
superfamily of Fasciola (15, 19, 36), the comparison of NEJ and adult 2D arrays 
revealed a dramatic reduction of FABP isoforms in NEJs (Figure 1a).  This absence 
of FABPs from the NEJ proteome included the slightly acidic FABPs, isoforms I and 
II (Figure 1a i), and the basic isoform, FABP III (Figure 1a ii).  As a result of these 
preliminary proteomes further FABP isoform delineation was to be conducted upon 
adult samples using selective to IPG strips (pH 4.7-5.9 for acidic FABPs and pH 7-10 
for basic FABPs) to provide maximum resolution. 
FABP sub-proteome of adult F. hepatica 
Separation of adult F. hepatica somatic homogenates on narrow and micro 
range IPG strips and subsequent SDS-PAGE resulted in identification of FABP 
isoforms belonging to the type I, II and III sub-families.  A total of 15 protein spots 
were consistently identified via Progenesis analysis lying below the 20 kDa marker 
and occupying the recognised FABP ‘zones’ (Figure 1b).  MSMS data from the 
peptides excised from 4.7-5.9 micro range gels (Figure 1c) confirmed that FABP II 
isoforms appear in four different locations on the gel, varying in pI as well as in 
molecular weight (Table 1). FABP I (Fh15) isoform was found in three locations of 
the same gel analysis. A discrepancy in pI and molecular weight between values 
calculated by Progenesis (5.3- 5.6/17.4-20.5 kDa) and those predicted from 
Genbank entries (5.93/14936.04 Da for FABPII, Q7M4G1 and 5.91/14712.08 Da for 
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Fh15, Q7M4GO) was observed. To account for multiple FABP locations, potential 
sites of post-translational phosphorylation were investigated and identified five 
Serine and Threonine residues for FABP I (Fh15) and three for FABP II predicted 
with high significance to be phosphorylated.  
MSMS data from the peptides excised from pH 7-10 narrow range gels (Figure 1d) 
confirmed that FABP III is the most abundant FABP isoform and was identified in five 
different locations on the gel, varying principally in pI (Table 1). FABP II was 
identified in two further locations and in both cases co-localised with FABP III. Of 
interest was the solitary identification of FABP III co-localised with a serine/threonine 
protein kinase. As with FABP I and II, FABP III potential sites of post-translational 
phosphorylation were investigated identifying three serine and one threonine 
residues predicted with high significance to be phosphorylated. Only two protein 
spots identified did not contain FABP isoforms. 
Potential Immune recognition of FABP isoforms 
Having identified the isoforms of FABP present in adult F. hepatica, somatic 
homogenate samples were then subjected to 1D Western blotting using a pooled 
bovine infection sera time course to reveal the dynamics of the FABP superfamily 
members and the host IgG response.  Somatic homogenate samples were probed 
with time course sera from week 0, naïve animals, to week 14 post infection 
(excluding week 10 post infection) to look for FABP interaction.  Data showed that an 
IgG response to proteins of the appropriate sizes could be observed from as early as 
2 weeks post infection (Figure S1A) with two bands visualised.  The extent of this 
IgG recognition persisted until 14 weeks post infection.  In order to determine if any 
of the FABP isoforms (FABP I, II or III) were responsible for the IgG recognition all 
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samples were subjected to 2DE profiling as described previously followed by 
Western blotting.  
The 2DE array, spanning pH 4.7-5.9, of the cytosolic fraction of adult liver fluke 
homogenate was transferred to NC membranes and assayed with sera from infected 
and naive cattle.  Pooled sera from week 8 post infection produced the strongest IgG 
response and thus selected to probe 2DE Western blot arrays.  The transfer of 
somatic samples to membranes for antibody testing was assessed using amido 
black staining (Figure S1b).  Once probed with week 8 sera only very weak IgG 
responses were seen.  This recognition was primarily to spots containing FABP I 
(Figure S1c, spots 2, 4 and 5 in Figure 1c) and extremely weakly to those spots 
containing FABP II (Figure S1c, spots 6, 7 and 8 in Figure 1c).  Importantly, the 
strongest, albeit weak, IgG response was to spot 2 which contained both FABP I and 
a translation initiation inhibitor (Figure S1c, spot 2 in Figure 1c). Thus, it is likely that 
the immune recognition of FABPs I-III is extremely low.  Importantly, naïve sera 
(week 0) showed no IgG response (Figure S1d).  IgG responses were also 
highlighted in an unresolved section of the gel at the pI 5.9 side of the gel. 
The 2-DE array (pH 7-10) of the cytosolic fraction of adult liver fluke homogenate 
was transferred to NC membranes and assayed with sera from infected and naive 
cattle.  As with acid FABP isoforms week 8 infection sera was chosen to screen the 
basic putative FABPs for immunoreactivity. However, no antibody recognition could 
be detected for any of the basic FABP isoforms or indeed any proteins lower than 
the 30 kDa marker (Data not shown).  
Transcript and phylogenetic analysis of FABP isoforms 
Available transcript and EST data sets from both F. hepatica and F. gigantica and 
the F. hepatica genome were searched for representative FABP superfamily 
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members.  All identified members representing known FABP isoforms I, II and III and 
potential new FABP isoforms were aligned with members of the known vertebrate 
FABP classes.  From the multiple alignment a phylogenetic tree was constructed to 
ascertain the Fasciola FABP clade structure.  The previously identified Fasciola 
FABP I, II and III clades were well conserved and most related to clades from the 
known vertebrate Heart (H, B, A, T and M-FABP) and Intestinal (I and K-FABP) 
FABP groups (Figure 2).  The FABP type I clade comprises the recombinant FABP I 
(Fh15) from F. hepatica and reveals a clear separation between representatives of 
both Fasciola species into two subclades.  This subclade structure is not replicated 
in clades II or III as there is a lack of F. gigantica FABP II representatives and the 
sequences of FABP III from both species are 100% identical at the amino acid level.  
A fourth novel clade (Bootstrap support 90%), termed FABP V, clustered near the 
known three isoforms but much closer to the known vertebrate classes, in particular 
the vertebrate keratinocyte and intestinal FABP isoforms.  Interestingly, the FABP 
Sm14 from S. mansoni clustered close to Fasciola FABP clade V.  Three further 
novel clades of Fasciola FABPs were identified with strong bootstrap support, 
termed FABP IV (99%), VI (91%) and VII (96%; Figure 2).  All three of these putative 
novel FABP clades, as with FABP clade I, also showed a distinct separation between 
representatives of F. hepatica and F. gigantica.  Both FABP clades VI and VII were 
most related to the vertebrate liver and ileal forms of vertebrate FABPs with FABP 
clade IV to a lesser extent.  
Representatives of the novel four FABP clades from both F. hepatica and F. 
gigantica were cloned and sequenced.  This revealed proteins of 132 (FABP IV), 134 
(FABP V), 162 (FABP VI) and 166 (FABP VII) amino acids in length.   The average 
amino acid sequence similarity to the previously identified Fasciola FABPs ranged 
Page 15 of 47
ACS Paragon Plus Environment
Journal of Proteome Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
16 
 
from as low as 22% to 48%.  Specifically, FABP IV was most similar to FABP I (24-
25%), FABP V to FABP III (48%), FABP VI to FABP II (24-25%) and FABP VII to 
FABP III (22%).  Initially, all sequencing was performed on adult cDNA however 
expression of all 4 novel FABPs was confirmed in NEJ cDNA (Data not shown).  All 
F. hepatica and F. gigantica clones for the novel FABP classes are included in 
Figure 2.  
Confirmation of novel FABP isoforms 
All four newly identified putative FABP sequences were confirmed as FABPs using 
bioinformatics.  As an initial comparison, the gene structures of the four new 
isoforms were compared to those of FABPs I, II and III (Figure 3a).  This analysis 
revealed that only the structure of FABP IV matched those of I-III.  FABP V only 
differed by 6 bp (3 bp in exon 2 and 3 bp in exon 4).  Of note were the dramatic 
increase in size of exon 4 in both FABP VI and VII. 
All novel FABP isoforms were then subjected to secondary structure prediction 
analysis to identify the characteristic ten anti-parallel β-strands comprising a β-barrel 
and the helix-turn-helix cap.  All novel FABP isoforms from both F. hepatica and F. 
gigantica were predicted to have the FABP characteristic structure (10 β-strands and 
2 α−helices; Figure 3b).  All four novel isoforms were also subjected to InterPro 
sequence analysis for FABP domain predictions.  In all cases, both IPR011038 
Calycin-like and IPR012674 Calycin were predicted for both Fasciola species 
isoforms.  Furthermore, three of the four isoforms (excluding FABP IV) were 
predicted to have IPR000463 Cytosolic fatty-acid binding properties.  Of note was a 
well conserved cytosolic fatty-acid binding signature in all novel FABP isoforms; in 
particular FABP V with 94.4% sequence identity to the recognised motif signature 
(Table 2; GKWKLVDSRDFDKVMVEL).  All four novel sequences were also 
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subjected to a SVMProt prediction to identify functional characterisation.  Novel 
FABPs were all identified as Lipid binding proteins, further confirming their status as 
FABPs, with the exception of FABP VI.  In this instance FABP VI was identified as a 
zinc binding protein.  As expected, all novel FABP isoforms lacked a signal peptide 
further confirming them as cytosolic FABP isoforms.  Importantly, both N-terminal 
residues G6 and W8 are conserved in all novel FABP isoforms.  
Expression of FABP isoforms IV and V  
Due to their similarity to the three previously known FABP isoforms both FABP IV 
and V from F. hepatica and F. gigantica were chosen for expression in E. coli for 
immunological characterisation.  Both proteins from both species were purified using 
Ni2+ affinity chromatography and assessed for purity using 1D and 2D SDS-PAGE in 
conjunction with ESI-MS for an accurate mass assessment.  All proteins were 
purified to a high level as assessed by both methods (Figure 4).  Both FABP IV 
(predicted molecular weight 15,073 Da and 16,351 Da with the Histag) and V 
(predicted molecular weight 15,372 Da and 16,650 Da with the Histag) had 
commonly observed Na+ adduct formation (mass shifts of 22 Da between peaks) and 
a shift of 63 Da from the expected molecular weight relating to ammonium formate 
(NCOONH4) adduct formation during ESI-MS analysis (Figure 4A).  FABP V was 
observed as a more basic isoform from 2D SDS-PAGE (approximate pI 8.4; Figure 
4C) than that of FBAP IV (Figure 4B).  Minor shifts from the predicted molecular 
weights were seen for both isoforms which may indicate lipid binding during 
purification as no delipidation steps were incorporated. 
Both expressed FABP isoforms were assessed for serum antibody responses using 
a time course of Fasciola hepatica-challenged and naïve bovine sera (weeks 0-14 
post infection).  FABP IV showed no IgM or IgG responses throughout a 14 week 
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infection (Data not shown).  However, FABP V from both F. hepatica and F. 
gigantica had observable IgM and IgG responses as assessed by Western blotting 
(Figure 5).  IgM responses towards FABP V were visualised strongly at week 4-6, 
whereas IgG responses were visualised earlier at weeks 2-4. 
A total of 41 Fasciola individuals were subjected to an analysis of FABP V to identify 
any potential sequence variation within the population (Data not shown).  This 
included 33 adult F. hepatica from 3 different populations (South Gloucester, 
Camarthen and Llanidloes; all UK) and 8 adult F. gigantica (North and South India).  
Upon analysis, only a few single amino acid polymorphisms (SAAPs) were identified 
between all Fasciola spp. FABP V sequences.   This was limited to just four of the 
individuals sequenced with a total of 4 SAAP sites.  A single SAAP site was localised 
in two individual F. hepatica from the Llanidloes population (Q66L and Y130N), a 
further SAAP was identified in a Northern India F. gigantica sample (Q66R) and 
finally two SAAPs in one F. gigantica sequence from the South of India (V69I and 
K87R).  Interestingly, 3 of the 5 SAAPs identified (those at sites 66 and 69) fall within 
a predicted epitope that spans amino acid residues 63-70. 
Absence of Novel FABP Isoforms in Exosome-like Vesicles As both FABP II and 
III have been previously identified in F. hepatica exosome-like vesicles (24) 
proteomic data was searched for all novel FABP isoforms.  Interestingly, none of the 
novel FABP isoforms were identified in exosome-like vesicles (Pers. comm. Marcilla 
June 2014).  
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Discussion 
Reductionist studies have proposed diverse roles in parasitism for FABP isoforms, 
including uptake/transport of fatty acids as there is limited synthesis in helminth 
worms, immune modulation via their fatty acid ligands and the sequestration of 
anthelmintics as a resistance mechanism.  However, in order to effectively 
investigate the function of the FABPs it is imperative to first resolve and fully 
delineate the complexity and novelty within the superfamily.  Hence, we have utilised 
a polyomics approach incorporating genomics, transcriptomics and proteomics to 
reveal a FABP superfamily from the pathogenic liver fluke parasite F. hepatica with 
seven distinct isoforms; four more than previously discovered.  
Our previous observations revealed a dominance of FABP abundance in adult liver 
fluke rather than the more pathogenic NEJs, where FABPs were significantly 
reduced in abundance.  Relatively low levels of FABPs in juvenile liver fluke 
compared to adults is replicated in other parasitic platyhelminths and thus not simply 
related to adult survival in the liver/bile environment.  For example, in schistosomes 
an increase of FABPs is observed from newly developed schistosomula through to 
lung stage schistosomula and with the greatest abundance of FABPs found in adults 
(46, 47) suggesting FABPs are important for development.  The differential 
expression of FABPs from F. hepatica may be explained by functional roles; namely 
intracellular transport and detoxification.  Intracellular FABPs function as fatty acid 
(FA) transport proteins (16, 18). Therefore, in the absence of FA synthesis in adult 
parasitic flatworms, high levels of FABPs may transport FAs that are taken up via 
uncharacterised tegumental mechanisms from the host environment (48).  However, 
within NEJs there is a high level of preformed/stored lipid to support initial host 
survival (49, 50) and likely a reduced requirement for fatty acid uptake and FABP 
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transporters, hence their dramatic reduction observed in 2DE arrays (Figure 1A).  
The greater abundance of adult liver fluke FABPs may be related to adult feeding 
patterns.  At the onset of blood feeding it has been suggested that FABPs are 
essential for the uptake of FAs from host blood (51).  Furthermore, FABPs 
sequestrate and remove haem, a toxic by-product of blood feeding responsible for 
hydrogen peroxide (H2O2) production if in the free form (52).  In support of this 
theory, antibodies directed towards F. hepatica FABPs can be observed around 2-4 
weeks post infection (53 and the present study) coinciding with migration through the 
liver and the onset of blood feeding behaviour.   
Delineating the adult FABP proteome revealed the three known Fasciola FABP 
isoforms, reported in the recent publication of the F. hepatica genome (45), in 
multiple locations within the 2DE arrays (3 locations for FABP I, 6 for FABP II and 5 
for FABP III); an observation often causing confusion over true isoform identification 
(54).  So why are the F. hepatica FABP isoforms resolving into numerous protein 
spots and will this impact upon future diagnostics or vaccines?  Multiple resolved 
versions of FABP isoforms have been attributed to post translational modification, 
especially phosphorylation (55), and tyrosine phosphorylation is known to 
inhibit/modulate the binding of FAs (56).  In mammals, phosphorylation of FABPs 
appears low >1% (54) but bioinformatics predicts multiple phosphorylation sites in 
Fasciola FABPs, tentatively suggesting a difference in FA transport regulation 
between host and parasite.  In contrast, multiple resolved versions of FABP isoforms 
could also be attributable to irreversible ligand or FA binding (54).  
Resolving the function of each FABP isoform is compounded by the complex 
diversity, tissue and temporal specificity and ligand preferences of each FABP 
isoform (16).  For example, FgFABP I and FgFABP III from F. gigantica have some 
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overlapping roles yet FgFABP I supports the male reproductive system and FgFABP 
III supports the female reproductive system (57).  It is likely that this distribution of 
FABPs I and III will be replicated within F. hepatica tissues.  In the current study, F. 
hepatica FABP isoforms I-III were assessed for host immune recognition.  Mirroring 
the study of Chunchob et al. (57) no immune recognition was observed to FABP 
isoform III using bovine sera.  However, recognition of a protein spot containing 
FABP isoform I was seen, unlike for FgFABP I.  However, the strongest, albeit weak, 
immune recognition identified was to a protein spot containing both FhFABP I and 
translation initiation inhibitor (TII).  Given the lack of immune recognition to other 
FhFABP I protein spots in the array the primary response seen may relate to TII.  
This is especially pertinent with the identification of TII in F. hepatica tegument 
preparations, both S2SS and UTCS fractions, of the study by Wilson et al. (20) and 
in surface preparations, both SPF and IPF protein fractions, from the study of 
Harcariz et al. (58).  It is likely that TII is exposed to the host immune system and 
thus elicit the immune response identified in the current study.   
We performed a bioinformatic analysis of currently available transcript and genomic 
databases for F. hepatica and F. gigantica to probe for the first time the complexity of 
the liver fluke FABP superfamily.  As with previous phylogenetic studies FABP 
isoforms I, II and III formed a distinct group close to the vertebrate H- and I-FABP 
groups.  FABP I isoforms had a clear separation related to Fasciola species not seen 
in FABP II or FABP III isoform groupings due to limited sequence data availability 
and 100% amino acid sequence identity between fasciolids respectively.   
Further phylogenetic analysis identified four new FABP isoforms represented in both 
F. hepatica and F. gigantica and in both adults and NEJs, namely isoforms IV-VII.  
All four of these novel isoforms were confirmed as FABPs using bioinformatics.  Only 
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FABP isoform VI did not conform to every bioinformatics analysis predicting a FABP; 
namely a SVMProt prediction did not identify FABP VI as a Lipid binding protein 
predicting a Zinc binding protein instead.  In this case, FABP VI was classified as a 
FABP on its gene structure (exons 1-3 matching known FABP exon structures), 
protein structure (10 β-strands and 2 α-helices) and its highly conserved cytosolic FA 
binding domain signature (88.9% amino acid identity). Phylogenetically, isoforms IV, 
VI and VII were split between F. hepatica and F. gigantica as seen with isoform I.  
Using bioinformatic analysis all novel sequences were confirmed as authentic FABP 
isoforms by analysing gene structures, sequence motifs and secondary structure 
prediction. 
FABP isoform V was closely related to isoforms I-III but closer to vertebrate I- and K-
FABPs.  Vertebrate I-FABPs are generally known to bind FAs only rather than 
additional ligands.  In addition, FAs bound to I-FABPs are also bound in a different 
conformation to the other vertebrate FABPs (FAs bind to I-FABPs in a bent 
conformation instead of a U shaped conformation when bound to alternative 
vertebrate FABPs) (59).  Therefore, it is possible that FABP V is expressed 
specifically for the uptake of FAs from the host, although binding similarities to I-
FABPs will require confirmation as the ligand binding residues of I-FABP (Y70, L72, 
A73, W82, Q115 and Y117) are not conserved in FABP isoform V (59).  
The three other novel Fasciola FABP isoforms, IV, VI and VII, clustered away from 
the previously known Fasciola FABPs and were located close to the vertebrate L- 
and IL-FABP groups.  As with the FABP I, II and III isoforms we would expect to 
identify multiple versions upon a 2DE array.  The potential of cysteine modification 
via glutathionylation or cysteinylation, related to the redox state of the host liver, may 
complicate distinguishing true FABP isoforms as seen for vertebrate L-FABP (54).  
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Vertebrate L-FABPs are distinctly different from other vertebrate FABP groups.  
Firstly, they differ in the FA uptake mechanism, which in L-FABPs occurs via 
diffusion (16) rather than collision as demonstrated for H- and I-FABPs.  
Furthermore, as a result of their large binding pocket, ligands of L-FABPs bind at a 
2:1 molar stoichiometry ratio as opposed to 1:1 in all others examined (60).  
Importantly, vertebrate L- and IL- FABPs are capable of binding FAs as well as bulky 
ligands such as bile salts, cholesterol and haem (61).  Whilst all of these abilities 
remain to be confirmed in the novel Fasciola FABP isoforms IV, VI and VII, it would 
seem logical that these isoforms could well be adapted for a ‘life in bile’ as a blood 
feeder.  Interestingly, two of the novel FABP isoforms, VI and VII, had a 31 and 33 
amino acid C-terminal extension respectively.  Whilst the role of these extensions is 
currently unknown they may well be involved in interactions or attachments to other 
proteins or for membrane association (62). 
It has been suggested that a reduced diversity of FABP isoforms in invertebrates 
compared to vertebrates represents a lower specificity for ligands but a larger 
repertoire of interactions within the cell (16).  In contrast, the number of FABP 
isoforms in Fasciolids has expanded suggesting potential specialisation of FABP 
isoforms.  The vertebrate groupings H-, I- and L-FABPs reflect their specific binding 
abilities (61).  Thus, it is likely that Fasciola FABPs may also segregate according to 
their binding abilities.  The separation of FABP isoforms I, II, III and V from isoforms 
IV, VI and VII may represent two clusters based upon their respective binding 
capabilities. 
Disappointingly, none of the newly recognised FABP isoforms (IV-VII) were identified 
during proteomic analysis.  This could potentially result from the quantity of protein in 
the identified protein spots, identified as FABPs I, II and III, supressing any 
Page 23 of 47
ACS Paragon Plus Environment
Journal of Proteome Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
24 
 
recognition of the novel FABP isoforms.  Alternatively, it may be that FABPs IV-VII 
may be of more importance in the juvenile stages of the parasite such is the case 
with cathepsin proteases (cathepsin L1, 2 and 5 in adults whereas cathepsin L3 and 
4 with cathepsin B in juveniles) (27).   
FABP isoforms IV and V were expressed as recombinant forms in order to further 
understand the immune responses directed to the FABP family for diagnostic or 
vaccine potential.  Despite its absence from F. hepatica exosome-like vesicles, 
FABP isoform V shows potential as a diagnostic or vaccine candidate with strong 
IgM and IgG responses seen in pooled bovine infection sera.  As diagnostics, 
Fasciola FABPs show promise with two studies by Allam and colleagues suggesting 
FABP for the diagnosis of F. gigantica infections in both buffalo and man (63, 64).  In 
both cases FABPs were purified from crude adult worm extracts, likely to contain 
multiple FABP isoforms.  Thus, FABP isoforms I-III are likely to dominate the 
preparation but the presence of FABP IV-VII cannot be discounted. Furthermore, 
Hillyer et al. (53) also noted that antibodies to FABP I could also be observed at 2-4 
weeks post infection highlighting the excellent potential of FABPs as diagnostics. 
However, to further improve diagnostic potential the correct choice of which FABP 
isoform to target is essential.  For example, from the evidence presented in the 
current study, poor recognition to FABP I-III in natural infections and strong IgM and 
IgG responses to FABP V from weeks 2-4, FABP isoform V may be a potential 
choice as a diagnostic. However, with the expanded FABP family, from three to 
seven members, each isoform must be investigated specifically to gauge the best 
choice for a diagnostic.  
As vaccine candidates, FABPs have also been studied in depth.  Early studies using 
FhFABPs looked promising with trials in mice revealing 69-78% protection.  
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Unfortunately, these protection rates did not translate well into cattle trials with two 
studies giving 31 and 55% protection (Vaccine trials reviewed by 65).  Poor 
translation into target animals was also observed in trials for protection against F. 
gigantica.  For example, in buffalo a 35.8% reduction in worm burdens with 
associated reductions in liver enzymes (AST) was observed (66).  However, this trial 
also demonstrated a high anti-fecundity effect (66).  As with other candidate 
vaccines based upon protein superfamilies the choice of which isoform to vaccinate 
with is key decision ensuring plasticity of the target is low (27).  Therefore, Fasciola 
FABP isoform V may be a strong candidate for novel vaccine trials perhaps as part 
of a combination therapy.  A potential combination therapy could incorporate FABP V 
and an immune suppressor component, such as FhGST-S1 (19, 67).  FABP 
potential could also be enhanced by conducting similarity studies between those 
isoforms eliciting an immune response (FABP isoforms I, II and V) which may reveal 
the structural details that are responsible for triggering this immune response in the 
host organism.  This could lead to the rational design of protein complexes that may 
prove to be more effective in vaccine trials than current vaccine candidates.   
 
Conclusions 
A poly-omics approach has successfully revealed the cytosolic FABP 
superfamily complement expressed in F. hepatica adults.  These have been 
classified into seven isoforms, types I-VII, with a potential clustering of isoforms into 
two groups; group one consisting of isoforms I, II, III and V and group two consisting 
of isoforms IV, VI and VII.  These two groupings may reflect their binding dynamics.  
Importantly, FABP isoform V from both F. hepatica and F. gigantica shows promise 
as a new diagnostic antigen or as a vaccine candidate. 
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Table 1.  Putative protein identifications of F. hepatica fatty acid binding proteins 
using MASCOT. Spectra from mass spectrometry were subjected to MSMS ion 
searches using MASCOT (Matrix Science) searching an in house EST database. 
Significant hits, at P = 5%, have a MASCOT score of 25 or greater. All significant 
EST hits were then subjected to BLAST analysis against GenBank to assign an 
identity to matching ESTs. Therefore, all reported accession numbers are from 
GenBank. NS: Not significant. 
 
Table 2. Fatty acid binding signature of novel fatty acid binding proteins.  The fatty 
acid binding signature of all four novel FABPs from both F. hepatica and F. gigantica 
are highly conserved, especially so for FABP V.  Residues shaded grey show 100 
suitability to the signature requirements.  A percentage match is given for the 18 
residue motif. 
 
Figure 1. Representative global protein arrays of F. hepatica FABPs.  F. hepatica 
ontogeny 2D SDS-PAGE protein arrays of a) newly excysted juvenile and b) adult F. 
hepatica.  Circled areas within the arrays localise known FABP isoforms I, II and III.  
Therefore, narrow range (pH 7-10) and micro range (pH 4.7-5.9) IPG strips were 
chosen as the most suitable range to effectively resolve the F. hepatica FABP 
members (denoted by dashed lines).  Both arrays were loaded with 250 µg of 
cytosolic protein and run on linear pH 3-10 IPG strips and on 14% acrylamide SDS-
PAGE.  Both arrays were Coomassie blue stained. c) Representative micro range 
(pH 4.7-5.9) and d) narrow range (pH 7-10) protein arrays of adult F. hepatica 
somatic samples for FABP location and identification.  Both c and d were loaded with 
1 mg of cytosolic protein, run on 14% acrylamide SDS-PAGE and Coomassie blue 
Page 37 of 47
ACS Paragon Plus Environment
Journal of Proteome Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
38 
 
stained.  Circled spots correspond to those proteins consistently present on 
averaged gels and their putative protein identifications can be found in Table 1. 
 
Figure 2.  Phylogenetic analysis of vertebrate and Fasciola FABPs to determine the 
clade structure of FABP isoforms present in F. hepatica and F. gigantica.  Neighbor-
joining phylogenetic tree constructed using amino acid sequences through MEGA v 
4.0 with 1000 bootstrapped support and a Poisson correction. All reported accession 
numbers are from Genbank.  Where sequences were identified in silico, only contig 
numbers are reported. Those from F. gigantica were taken from the study of Young 
et al. (39) and those from F. hepatica were taken from Young et al. (39) or transcripts 
produced by the University of Liverpool (EBI-ENA archive ERP000012: An initial 
characterization of the F. hepatica transcriptome using 454-FLX sequencing) 
Sequences from F. gigantica NEJs were sequenced in house. 
 
Figure 3. Characterisation of novel FABP isoforms. A) Bioinformatic characterisation 
of F. hepatica fatty acid binding protein gene structures.  All three currently identified 
FABP isoforms (I, II and III) were identified within the F. hepatica genome (45) and 
there intron-exon structures identified.  These were compared to those of the four 
novel FABP isoforms (IV, V, VI and VII).  Exons shaded in grey indicate deviation 
from those structures identified within isoforms I, II and III.  Reported exon sizes are 
in nucleotide bp. B) Fatty acid binding protein secondary structure prediction.  A 
multiple alignment of all four novel FABP isoforms from both F. hepatica and F. 
gigantica were subjected to secondary protein structure prediction to identify the 
FABP characteristic structure containing 10 β-strands and 2 α−helices.  Predictions 
were carried out using PsiPred Version 3.2 (68).   Each β-strand or α−helix is boxed 
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and numbered.  The extended C-terminal of isoforms VI and VII are apparent with 
additional β-strand or α−helix predictions shown in grey shaded dashed boxes or 
open dashed boxes respectively.  The three domains that constitute the lipocalin 
binding domain are boxed in blue.  Arrowed are the starting and ending residues of 
the IPR000463 Cytosolic fatty-acid binding domain signature within domain 1. The 
GXW triplet domain in domain 1 is underlined in green.  All predicted 
phosphorylation sites (S, T and Y) are boxed in red. 
 
Figure 4.  Expression of recombinant protein forms of novel FABP isoforms A) 
Purification of FABP IV from F. hepatica with purity revealed via ESI mass spectrum 
of the Ni2+ affinity purified rFhFABP IV showing the molecular weight at 16287.7 ± 
0.49 Da (with 6 sodium adduct peaks). Data for FABP V not shown.  B) Purity was 
also assessed with a 2D SDS-PAGE protein array run on 14% SDS-PAGE and 
Coomassie blue stained. C) Purification of FABP V from F. hepatica assessed with a 
2D SDS-PAGE protein array run on 14% SDS-PAGE and Coomassie blue stained. 
 
Figure 5.  Antibody responses to novel Fasciola FABP isoform V. Representative 
Western blots of rFhFABP V samples looking for both IgM and IgG responses   
rFhFABP V was run on 14% acrylamide SDS-PAGE, electro-transferred to 
membranes and Western blotted with pooled bovine infection sera from week 0, 
naïve sera, to week 14 post infection as the primary antibody with anti-bovine IgM (a) 
or anti-bovine IgG (b) as the secondary antibody.  A F. hepatica somatic sample (S) 
was also included and as a positive control using sera from week 8 post infection. 
White arrows indicate the start of immune recognition.  Black arrow highlights the F. 
hepatica cathepsin L proteases recognised by bovine IgG (36). 
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Table 1 1 
Spot
Mascot 
Score EST Number BLAST Score
Accession 
Number Putative Identification Species
Sequence 
Coverage
Unique 
Peptides
Nominal 
Mass pI
Fasciola FABP 
Clade
1 260 Fhep06b08.q1k 1.00E-38 XP_002576820 Translation initiation inhibitor Schistosoma mansoni 66 4 10043 5.13 -
85 HAN5013c02.q1kT3 2.00E-45 XP_002576820 Translation initiation inhibitor Schistosoma mansoni 26 2 12840 4.71 -
2 357 Fhep06b08.q1k 1.00E-38 XP_002576820 Translation initiation inhibitor Schistosoma mansoni 66 4 10043 5.13 -
149 HAN5013c02.q1kT3 2.00E-45 XP_002576820.1 Translation initiation inhibitor Schistosoma mansoni 26 2 12840 4.71 -
68 Fhep50d03.q1k 6.00E-56 Q7M4G0 Fatty acid-binding protein Fh15 (Type I) F. hepatica 11 1 9367 6.26 I
3 88 Fhep06b08.q1k 1.00E-38 XP_002576820 Translation initiation inhibitor Schistosoma mansoni 36 2 10043 5.13 -
52 Fhep20f11.q1k 8.00E-89 Q7M4G1 Fatty acid-binding protein Type II F. hepatica 49 7 15327 5.21 II
4 265 Fhep46d02.q1k 1.00E-80 Q7M4G0 Fatty acid-binding protein Fh15 (Type I) F. hepatica 39 5 19484 6.33 I
194 Fhep50d03.q1k 6.00E-56 Q7M4G0 Fatty acid-binding protein Fh15 (Type I) F. hepatica 54 4 9367 6.26 I
5 99 Fhep50d03.q1k 6.00E-56 Q7M4G0 Fatty acid-binding protein Fh15 (Type I) F. hepatica 61 5 9367 6.26 I
54 Fhep46d02.q1k 1.00E-80 Q7M4G0 Fatty acid-binding protein Fh15 (Type I) F. hepatica 43 6 19484 6.33 I
6 227 Fhep20f11.q1k 8.00E-89 Q7M4G1 Fatty acid-binding protein Type II F. hepatica 65 9 15327 5.21 II
208 HAN5004a01.p1kaT7 1.00E-89 Q7M4G1 Fatty acid-binding protein Type II F. hepatica 62 10 14869 5.63 II
7 109 Fhep20f11.q1k 8.00E-89 Q7M4G1 Fatty acid-binding protein Type II F. hepatica 65 8 15327 5.21 II
8 307 Fhep20f11.q1k 8.00E-89 Q7M4G1 Fatty acid-binding protein Type II F. hepatica 77 10 15327 5.21 II
248 HAN5004a01.p1kaT7 1.00E-89 Q7M4G1 Fatty acid-binding protein Type II F. hepatica 68 10 14869 5.63 II
9 115 HAN3004-1f09.p1k 2.00E-89 Q9U1G6 Fatty acid-binding protein Type III F. hepatica 38 4 14550 7.82 III
77 Fhep20f11.q1k 8.00E-89 Q7M4G1 Fatty acid-binding protein Type II F. hepatica 29 3 15327 5.21 II
10 107 HAN3004-1f09.p1k 2E-89 Q9U1G6 Fatty acid-binding protein Type III F. hepatica 38 4 14550 7.82 III
29 Fhep20f11.q1k 8E-89 Q7M4G1 Fatty acid-binding protein Type II F. hepatica 13 1 15327 5.21 II
11 112 HAN3004-1f09.p1k 2E-89 Q9U1G6 Fatty acid-binding protein Type III F. hepatica 45 5 14550 7.82 III
12 153 HAN3004-1f09.p1k 2E-89 Q9U1G6 Fatty acid-binding protein Type III F. hepatica 55 6 14550 7.82 III
153 HAN5010e10.q1kT3 3.00E-87 Q9U1G6 Fatty acid-binding protein Type III F. hepatica 61 7 14531 6.73 III
13 109 HAN3004-1f09.p1k 2E-89 Q9U1G6 Fatty acid-binding protein Type III F. hepatica 31 3 14550 7.82 III
30 Fhep08b02.q1k 5.5 ZP_06970083 Serine/threonine protein kinase Ktedonobacter racemifer 9 1 8693 8.74 -
14 46 Fhep42c03.q1k 6.00E-15 Q5DC69 10 kDa heat shock protein Schistosoma japonicum 56 2 4688 4.81 -
43 HAN5022f11.q1kT3 2.00E-54 AAP06016 SJCHGC01960 protein (10 kDa heat shock protein) Schistosoma japonicum 61 5 10799 9.02 -
15 NS - - - - - - - - - -  2 
3 
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Table 2 4 
 
Signature requirement 
 
 
+ - + 
 
+ 
  
- 
 
+ + + 
 
+ + - - + % Motif 
Match Sequence GSAIVK FE FYW X LIVMF X X K X NHG FY DE X LIVMFY LIVM N G LIVMAKR 
Fhep FABPIV G K W K L D S Y E N V D A I L N M L 88.9 
Fgig FABPIV G K W K L D S Y E N V D A I L N M L 88.9 
Fhep FABP V G K W K L V D S R D F D K V M V E L 94.4 
Fgig FABP V G K W K L V D S R D F D K V M V E L 94.4 
Fhep FABPVI G E W E A T G H R N F S S I L A E I 83.3 
Fgig FABPVI G E W E A T G Q E N F S S I L A E I 83.3 
Fhep FABPVII G E W K C V E C S N L E P V M I E I 83.3 
Fgig FABPVII G E W K C V E C S N L E P V L I E V 83.3 
 5 
 6 
7 
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Figure 2  
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Figure 3  
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Figure 4  
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Figure 5  
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